8
Participants
Start Date
June 11, 2020
Primary Completion Date
May 10, 2021
Study Completion Date
May 10, 2021
PF-06439535 (CN)
15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
Bevacizumab-EU
15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
Paclitaxel
175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Carboplatin
AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Jinan Central Hospital, Jinan
Tianjin Medical University General Hospital, Tianjin
Dongguan People's Hospital, Dongguan
Affiliated Hospital of Hebei University, Baoding
Lead Sponsor
Pfizer
INDUSTRY